FDA Approves Alectinib for ALK-Positive Non-Small Cell Lung Cancer



The FDA has approved alectinib to treat patients with metastatic ALK-positive non-small cell lung cancer who have stopped responding to or who are unable to tolerate crizotinib.



Source link

Comments are closed.